Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

MLA

Tycel J. Phillips, et al. “Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma.” Blood, vol. 140, Nov. 2022, pp. 178–80. EBSCOhost, https://doi.org/10.1182/blood-2022-157777.

APA

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L’Étang, David Carlile, Ben Byrne, Naseer Qayum, & Carmelo Carlo-Stella. (2022). Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma. Blood, 140, 178–180. https://doi.org/10.1182/blood-2022-157777

Chicago

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, et al. 2022. “Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma.” Blood 140 (November): 178–80. doi:10.1182/blood-2022-157777.